Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations

Introduction and Objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers’ willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers’ willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil’s regulatory chamber of pharmaceutical products market for the commercialization of Dengvaxia(®) for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population

Resolução extrajudicial de conflitos entre consumidores e operadoras de planos de saúde

A Resolução Extrajudicial de Conflitos na ANS se dá por meio da Notificação de Intermediação Preliminar (NIP). A NIP consiste em instrumento que visa à solução de conflitos entre consumidores e operadoras de planos de saúde, em decorrência de demandas de negativa de cobertura assistencial. A NIP objetiva conferir um tratamento mais célere e eficaz às reclamações de consumidores à ANS. A mediação possibilita que a operadora repare sua conduta irregular, evitando-se, assim, a abertura de processo administrativo e judicial, com a resolução das reclamações. A NIP demonstrou grande potencial indutor corretivo de falhas do processo de trabalho das operadoras, possibilitando ações concertadas de mediação e de fiscalização indutora. A NIP alcançou índices de resolutividade (medida do total de reclamações que são finalizadas no âmbito da NIP sem necessidade de abertura de processo administrativo) de 65%, 68,8% e 78,4%, nos anos de 2010, 2011 e 2012, respectivamente.Número de páginas: 16 p.Administração PúblicaInovaçãoSaúdeIniciativa premiada no 19º Concurso Inovação na Gestão Pública Federal sob responsabilidade de Jacqueline Figueiredo de Lima Pauxis, Gerente. Ações premiadas no 19º Concurso Inovação na Gestão Pública Federal – 2014. Área temática: melhoria dos processos de trabalho